Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

–  Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively

–  Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period